Linganisha mbinu

	POEM (Kipimo cha Eczema Kinachozingatia Mgonjwa)	EASI (Eczema Area and Severity Index)	Kielezo cha SCORAD (Kupima Ukali wa Ugonjwa wa Ngozi unaosababishwa na Mzio)
Nyanja	Dermatolojia	Dermatolojia	Dermatolojia
Familia	Process / pipeline	Process / pipeline	Process / pipeline
Mwaka wa asili	2004	2001	1993
Mwanzilishi	Charman CR, Venn AJ, Williams HC	Hanifin JM, Thurston M	European Task Force on Atopic Dermatitis (ETFAD)
Aina	Self-report	Clinician-rated	Clinician-rated
Chanzo asilia	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.	Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology. 2001;10(1):11-18.	Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19.
Majina mbadala	POEM Score	EASI Index	SCORAD Index
Zinazohusiana	2	2	3
Muhtasari	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.	The EASI is a structured, clinician-administered tool for assessing the extent and intensity of atopic dermatitis across the body. Developed by Hanifin and colleagues in 2001, it divides the body into four regions with weighted area factors, ensuring proportional contribution to total score. EASI has become the primary objective severity measure in atopic dermatitis clinical trials and is recommended by international regulatory authorities (FDA, EMA).	The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice.